These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12566926)

  • 21. Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate.
    Twomey C; McCarthy JV
    FEBS Lett; 2006 Jul; 580(17):4015-20. PubMed ID: 16814287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The binding and phosphorylation of Thr231 is critical for Tau's hyperphosphorylation and functional regulation by glycogen synthase kinase 3beta.
    Lin YT; Cheng JT; Liang LC; Ko CY; Lo YK; Lu PJ
    J Neurochem; 2007 Oct; 103(2):802-13. PubMed ID: 17680984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropathogenic role of adenylate kinase-1 in Aβ-mediated tau phosphorylation via AMPK and GSK3β.
    Park H; Kam TI; Kim Y; Choi H; Gwon Y; Kim C; Koh JY; Jung YK
    Hum Mol Genet; 2012 Jun; 21(12):2725-37. PubMed ID: 22419736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
    Avila J; Wandosell F; Hernández F
    Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Streptomyces metabolite anhydroexfoliamycin ameliorates hallmarks of Alzheimer's disease in vitro and in vivo.
    Leirós M; Alonso E; Rateb ME; Ebel R; Jaspars M; Alfonso A; Botana LM
    Neuroscience; 2015 Oct; 305():26-35. PubMed ID: 26247694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-related changes in glycogen synthase kinase 3beta (GSK3beta) immunoreactivity in the central nervous system of rats.
    Lee SJ; Chung YH; Joo KM; Lim HC; Jeon GS; Kim D; Lee WB; Kim YS; Cha CI
    Neurosci Lett; 2006 Dec; 409(2):134-9. PubMed ID: 17046157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression.
    Pláteník J; Fišar Z; Buchal R; Jirák R; Kitzlerová E; Zvěřová M; Raboch J
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Apr; 50():83-93. PubMed ID: 24334212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of Tau with Fe65 links tau to APP.
    Barbato C; Canu N; Zambrano N; Serafino A; Minopoli G; Ciotti MT; Amadoro G; Russo T; Calissano P
    Neurobiol Dis; 2005 Mar; 18(2):399-408. PubMed ID: 15686969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular modeling and molecular dynamics simulation studies of the GSK3β/ATP/substrate complex: understanding the unique P+4 primed phosphorylation specificity for GSK3β substrates.
    Lu SY; Jiang YJ; Zou JW; Wu TX
    J Chem Inf Model; 2011 May; 51(5):1025-36. PubMed ID: 21495724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockage of GSK3β-mediated Drp1 phosphorylation provides neuroprotection in neuronal and mouse models of Alzheimer's disease.
    Yan J; Liu XH; Han MZ; Wang YM; Sun XL; Yu N; Li T; Su B; Chen ZY
    Neurobiol Aging; 2015 Jan; 36(1):211-27. PubMed ID: 25192600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes.
    Medina M; Avila J
    Expert Rev Neurother; 2013 May; 13(5):495-503. PubMed ID: 23621307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced insulin-induced phosphatidylinositol-3-kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease.
    Castri P; Iacovelli L; De Blasi A; Giubilei F; Moretti A; Tari Capone F; Nicoletti F; Orzi F
    Eur J Neurosci; 2007 Nov; 26(9):2469-72. PubMed ID: 17986027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P2 purinergic receptors signal to glycogen synthase kinase-3beta in astrocytes.
    Neary JT; Kang Y
    J Neurosci Res; 2006 Aug; 84(3):515-24. PubMed ID: 16810687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypothalamic glycogen synthase kinase 3β has a central role in the regulation of food intake and glucose metabolism.
    Benzler J; Ganjam GK; Krüger M; Pinkenburg O; Kutschke M; Stöhr S; Steger J; Koch CE; Ölkrug R; Schwartz MW; Shepherd PR; Grattan DR; Tups A
    Biochem J; 2012 Oct; 447(1):175-84. PubMed ID: 22849606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo.
    Bitner RS; Nikkel AL; Markosyan S; Otte S; Puttfarcken P; Gopalakrishnan M
    Brain Res; 2009 Apr; 1265():65-74. PubMed ID: 19230830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FXR1P is a GSK3β substrate regulating mood and emotion processing.
    Del'Guidice T; Latapy C; Rampino A; Khlghatyan J; Lemasson M; Gelao B; Quarto T; Rizzo G; Barbeau A; Lamarre C; Bertolino A; Blasi G; Beaulieu JM
    Proc Natl Acad Sci U S A; 2015 Aug; 112(33):E4610-9. PubMed ID: 26240334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycogen synthase kinase 3: a drug target for CNS therapies.
    Bhat RV; Budd Haeberlein SL; Avila J
    J Neurochem; 2004 Jun; 89(6):1313-7. PubMed ID: 15189333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual effects of increased glycogen synthase kinase-3β activity on adult neurogenesis.
    Fuster-Matanzo A; Llorens-Martín M; Sirerol-Piquer MS; García-Verdugo JM; Avila J; Hernández F
    Hum Mol Genet; 2013 Apr; 22(7):1300-15. PubMed ID: 23257288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of GSK3β by pharmacological modulation of sphingolipid metabolism occurs independently of ganglioside disturbance in a cellular model of Alzheimer's disease.
    Noel A; Ingrand S; Barrier L
    Exp Neurol; 2015 Sep; 271():308-18. PubMed ID: 26115843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease.
    Bitner RS; Markosyan S; Nikkel AL; Brioni JD
    Neuropharmacology; 2011; 60(2-3):460-6. PubMed ID: 21044639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.